References
- Walker B, Barrett S, Polasky S, et al. Environment. Looming global-scale failures and missing institutions. Science. 2009;325:1345–1346.
- Spellberg B, Blaser M, Guidos RJ, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52:S397–S428.
- Bergen PJ, Landersdorfer CB, Lee HJ, et al. ‘Old’ antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis. 2012;25:626–633.
- Landman D, Georgescu C, Martin DA, et al. Polymyxins revisited. Clin Microbiol Rev. 2008;21:449–465.
- Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59:88–94.
- Tsala M, Vourli S, Georgiou PC, et al. Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints. J Antimicrob Chemother. 2018;73:953–961.
- CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 10th ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2015. https://clsi.org/standards/products/microbiology/documents/m07/
- Garcia LS. Clinical microbiology procedures handbook. 3rd ed. Washington (DC): ASM Press; 2010.
- CLSI. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute; 2015. https://clsi.org/standards/products/microbiology/documents/m100/
- EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0. Växjö, Sweden: The European Committee on Antimicrobial Susceptibility Testing; 2018. http://www.eucast.org/clinical_breakpoints/
- Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161–168.
- Chew KL, La MV, Lin RTP, et al. Colistin and polymyxin B susceptibility testing for carbapenem-resistant and mcr-positive Enterobacteriaceae: comparison of sensititre, microscan, vitek 2, and Etest with broth microdilution. J Clin Microbiol 2017;55:2609–2616.
- van der Heijden IM, Levin AS, De Pedri EH, et al. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins. Ann Clin Microbiol Antimicrob. 2007;6:8.
- Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol. 2001;39:183–190.
- Sader HS, Rhomberg PR, Farrell DJ, et al. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. Diagn Microbiol Infect Dis. 2015;83:379–381.
- Bergen PJ, Li J, Rayner CR, et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:1953–1958.
- Cai Y, Lee W, Kwa AL. Polymyxin B versus colistin: an update. Expert Rev Anti Infect Ther. 2015;13:1481–1497.
- Vardakas KZ, Falagas ME. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;49:233–238.
- Li J. Difficulty in assaying colistin methanesulphonate. Clin Microbiol Infect. 2005;11:773–774.
- Humphries RM. Susceptibility testing of the polymyxins: where are we now? Pharmacotherapy. 2015;35:22–27.
- Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30:557–596.
- Vasoo S. Susceptibility testing for the polymyxins: two steps back, three steps forward? J Clin Microbiol. 2017;55:2582–2573.
- Tan TY, Ng SY. Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin. Clin Microbiol Infect. 2007;13:541–544.
- Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol. 2010;48:3558–3562.
- Nation RL, Li J, Cars O, et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015;15:225–234.